Recent Updates — FBLG

FibroBiologics, Inc. closed a private placement with Peak One Opportunity Fund, L.P., issuing a $1.2 million principal amount convertible debenture sold for $1.02 million at a 15% original issue discount. The company also issued 125,000 restricted common stock commitment shares and paid a $20,000 fee to the investor. The zero-percent interest debenture matures on October 8, 2027, with interim payments due in April and July 2027. Conversion is permitted only following an Event of Default at a fixed price of $0.78 per share, subject to a cap of 1,671,094 shares. FibroBiologics develops biologics for fibrotic diseases.

FibroBiologics, Inc. closed a private placement on September 15, 2026, raising approximately $0.5 million in gross proceeds from Hamid Khoja, Ph.D., the company's Chief Scientific Officer. The transaction involved the sale of 298,508 shares of common stock and accompanying warrants to purchase an equal number of shares at a combined price of $1.675 per unit, priced at-the-market under Nasdaq rules based on the September 14 closing bid. Each warrant carries an exercise price of $1.55 per share, is immediately exercisable, and expires five years from issuance. Shareholders also approved the issuance of up to 8,448,980 shares issuable upon the exercise of outstanding warrants under a June 2026 Securities Purchase Agreement and a November 2025 engagement letter with H.C. Wainwright & Co., LLC. The net proceeds will be used for general corporate purposes and working capital. FibroBiologics is a clinical-stage biotechnology company developing therapeutics for chronic diseases using fibroblast cells.

FibroBiologics, Inc. entered into a securities purchase agreement on September 15, 2026, with Hamid Khoja, Ph.D., its Chief Scientific Officer, for a private placement of 298,508 shares of common stock and accompanying warrants to purchase an equal number of shares. The offering price was $1.675 per share and warrant combination, generating approximately $0.5 million in gross proceeds before expenses. The warrants carry a $1.55 exercise price and expire five years from issuance. Proceeds are intended for general corporate purposes and working capital. FibroBiologics operates in the biotechnology industry, focusing on developing therapies for fibrotic diseases.

FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of its Board of Directors, effective August 20, 2026, with his term expiring at the 2028 annual meeting. Mr. Steinberg will receive compensation consistent with other non-employee directors and signed a standard indemnification agreement. The company operates in the biotechnology industry, developing therapeutics for chronic diseases using fibroblasts.

Matt Link resigned from the Board of Directors of FibroBiologics, Inc. effective July 2, 2026. On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D., a former NASA Astronaut and Professor at the University of Pittsburgh School of Medicine, as a Class III director. Dr. Rubins will also serve on the Audit, Compensation, and Governance and Nominating Committees until the 2029 annual meeting. FibroBiologics, Inc. is a biotechnology company.